Ashkon Software



LJPC - La Jolla Pharmaceutical Company

LJPC Intraday Chart

LJPC Profile

La Jolla Pharmaceutical Company logo

La Jolla Pharmaceutical Company, trading under the ticker symbol LJPC, is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for severe diseases that have significant unmet medical needs. The company is headquartered in San Diego, California.

La Jolla Pharmaceutical Company was founded in 1989 and has a pipeline of proprietary drug candidates that target a range of severe diseases, including severe hypotension, septic shock, and various types of cancer. The company's lead product candidate is GIAPREZA (angiotensin II), a synthetic form of a natural hormone that regulates blood pressure.

GIAPREZA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with septic or other distributive shock who remain hypotensive despite adequate volume resuscitation. La Jolla Pharmaceutical Company has also received approval for GIAPREZA in various other countries.

As of its most recent financial filings, La Jolla Pharmaceutical Company had cash, cash equivalents, and restricted cash of approximately $221 million, which is expected to provide the company with sufficient resources to fund its operations and advance its pipeline of drug candidates.

Investors considering an investment in La Jolla Pharmaceutical Company should carefully evaluate the company's financial performance, competitive position, and growth prospects. The biopharmaceutical industry is highly competitive, and the success of drug development programs is uncertain.

Despite these challenges, La Jolla Pharmaceutical Company has made significant progress in advancing its pipeline of drug candidates and has a strong track record of innovation and collaboration with leading academic institutions and pharmaceutical companies. The company's lead product candidate, GIAPREZA, has received regulatory approval in the United States and various other countries, and the company continues to advance its pipeline of drug candidates through clinical development and regulato


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer